According to a recent market study published by Growth Market Reports, titled, “Global Remifentanil Hydrochloride Market by Type, By Application, By Distribution Channel, and By Region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 272.2 Million in 2022 and is anticipated to expand at a growth rate of 2.8% by 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/5252

Remifentanil Hydrochloride is a relatively new ultrashort action opioid, which is a recent addition to the group of narcotic analgesics, that produces strong analgesia without causing prolonged respiratory depression. It is structurally unique and possesses an ester linkage that renders it susceptible to hydrolysis to inactive metabolites by nonspecific plasma & tissue esterases. This metabolic pathway is responsible for its (remifentanil hydrochloride) unique attenuation effect. It was developed in the early 1990s, introduced into clinical use in 1996, and given global approval for perioperative usage. It is twice as potent as fentanyl and 100–200 times more potent than morphine. It has become increasingly popular in clinical practice, due to its unique pharmacokinetic properties and potential advantages over other opioids. Remifentanil has certain pharmacokinetic features, including an exceptional clearance of almost 3 liters per minute, a brief half-life of 3 to 10 minutes, and a short time to peak effect of about 1.6 minutes, as the effect-site concentration of remifentanil reaches a peak within 1.1 minutes only. In addition, remifentanil has a relatively rapid onset of action and a predictable dose-response relationship, which makes it easy to use in clinical practice. It also has minimal accumulation, which seems advantageous in patients with renal or hepatic impairment.

The Global Remifentanil Hydrochloride Market has been segmented in terms of type, application, distribution channel, and region. In terms of type, the Global Remifentanil Hydrochloride Market is split into 1mg/Vial, 2mg/Vial, and 5mg/Vial. Based on application, the market is divided into Endotracheal Intubation Operation, Neurosurgery, Outpatient surgery, Postoperative analgesia, and Others. In terms of distribution channel, the market is split into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Considering regions, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Key Takeaways from the Study

  • Key Players in the Global Remifentanil Hydrochloride Market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Novartis AG (Sandoz International GmbH), Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, and B. Braun SE These players held a major share of the global Remifentanil Hydrochloride Market in 2021.
  • Strength of drug products is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety. 5mg/Vial refers to the quantity of active ingredient present in the vial, which 5 milligrams of the base form of remifentanil HCl respectively. This type of FDA-approved remifentanil hydrochloride is provided by players such as Teva Pharmaceutical Industries, Fresenius SE & Co. KGaA, and others.
  • Outpatient surgery is anticipated to account for a remarkable revenue in 2022 as healthcare facilities providing this type of surgery are focused on providing surgical care without the need for the patient to stay in the hospital overnight. Anesthesia such as remifentanil hydrochloride used in ambulatory/outpatient has proven to be safe, convenient, and cost-effective.
  • Retail Pharmacies is anticipated to grow at a CAGR of 2.5% during the forecast period as it is the most common type of pharmacy that allows the public access to their medications. Most retail pharmacies have a commercial store with a combination of medicinal goods only available with a prescription and those with that can be purchased over-the-counter. According to OCED, in 2019, the number of community pharmacies per 100,000 people ranged from 9 in Denmark to 88 in Greece, with an average of 28 across OECD countries.
  • Based on regions, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.  Europe accounted for a significant share of the market in 2021, due to the changing lifestyle and rising focus on R&D and design and quality of innovative products. Venous thromboembolism is a key cause of death and disability in the UK and the Rest of Europe. In Europe, the rising production of environmentally friendly and safe injecting devices such as pre-filled syringes.
  • In terms of countries, the market in Europe is segregated into Italy, Germany, France, the UK, Spain, Russia, and the Rest of Europe. The market in the UK is projected to expand at a CAGR of 3.4% during the forecast period. Remifentanil hydrochloride is becoming significantly popular in the region, owing to the rising demand for surgical procedures in the region. This is anticipated to boost the market of remifentanil hydrochloride in the coming years. For instance, according to the National Institutes of Health (NIH), the total number of surgical procedures carried out in England and Wales in 2020 was ~31,02,674. Moreover, as per the Royal College of Surgeons (RCS) England approximately 4.7 Mn surgical admissions were reported in 2013-2014 in England. This increasing number of medical surgeries is boosting the market for remifentanil hydrochloride.

Report Scope

Report Metric

Details

Market Value in 2021

US$ 272.2 Million

Market Growth Rate (from 2022 to 2031)

2.8%

Historical Data

2016 to 2021

Base Year

2022

Forecast Period

2023 – 2031

Units Considered

Value (US$ Million)

Market Segments

By Type, By Application, By Distribution Channel, and By Region

Key Companies Profiled

Teva Pharmaceutical Industries Ltd, Viatris Inc, Novartis AG (Sandoz International GmbH), Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, and B. Braun SE

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience

  • Supply-side: Vendor, Manufacturer, Distributors, Supplier, Retailer.
  • Regulatory Side: Concerned government authorities, and other approved regulatory bodies.